Scott Kellen - 01 Jun 2025 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Jun 2025, 16:16:00 UTC
Prior SEC filing
03 Jun 2024
Next SEC filing
03 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Scott Kellen

Key filing fact

Scott Kellen filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 03 Jun 2025.

Key facts

  • This page summarizes Scott Kellen's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 03 Jun 2025, 16:16.

Change

  • Previous filing in this sequence was filed on 03 Jun 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001490476 Primary reporting owner

Kellen Scott

Relationship
CFO & Secretary
Address
301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS
Signature
/s/ Scott Kellen
Signature date
03 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMAC holding

Voting Common Shares, no par value per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
32,290
Date
01 Jun 2025
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMAC transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+225,000
Change %
Price
$0.000000
Shares after
225,000
Date
01 Jun 2025
Ownership
Direct
Underlying class
Common Shares
Underlying amount
225,000
Exercise price
$4.11
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .